ThinkstockThe drug and pharmaceutical sector is supposed to be a defensive one by nature, even if this week’s government shutdown and impending debt ceiling weighed heavily on biotech stocks. Credit Suisse’s Vamil Divan has…
ThinkstockThe field of pharmaceuticals is very well established and often is considered to be a very defensive sector. As such, investors flock to the drug sector in times of uncertainty. But what about the…
ThinkstockA malaria vaccine is supposed to be a good thing. Right? Unfortunately that all depends. GlaxoSmithKline PLC (NYSE: GSK) currently plans to seek marketing approval for the first malaria vaccine next year. The British…
ThinkstockEnteroMedics Inc. (NASDAQ: ETRM) may be a largely unknown microcap stock to most investors. The company is in the development stages of making medical devices using neuroblocking technology to treat obesity, metabolic diseases and…
ThinkstockMerck & Co. (NYSE: MRK) announced it would rid itself of 8,500 workers, many of whom work in the big pharmaceutical company’s R&D operations. Since the return on research investment at Merck and its…
ThinkstockDrugmaker Merck & Co. Inc. (NYSE: MRK) announced Tuesday morning that it will fire another 8,500 employees in an effort to “sharpen” the company’s focus on R&D and returns to shareholders. The 8,500 job…
via Wikimedia CommonsIt looks like Congress and the president still cannot figure out how to play well with each other, and now we have another impending government shutdown. The reality is that some government…
ThinkstockNektar Therapeutics (NASDAQ: NKTR) may have just burned a serious bridge for its future. The company is developing drugs for pain management and for cancer, and now its investigational drug for chronic pain turned…
ThinkStockLast year, just under 15% of the U.S. population did not have health insurance coverage. But as the different stages of the Affordable Care Act roll out over the next few years — and…
Thinkstock Cancer-treatment company Foundation Medicine Inc. (NASDAQ: FMI) held its initial public offering (IPO) Wednesday morning. The company sold 5.9 million shares at an offering price of $18 a share, above its proposed range…
ThinkstockCredit Suisse has initiated research coverage on the so-called contract services organizations, or CROs. The firm’s Jeffrey Bailin started the sector with a Market Weight rating, but the reality is that three of the…
ThinkstockDespite Republican efforts to defund the Affordable Care Act, or Obamacare, it is looking increasingly likely that the program will begin enrollment into the new health care exchanges beginning next week, on Tuesday, October…
ThinkstockGoogle Inc. (NASDAQ: GOOG) is known for many efforts outside of traditional search and traditional technology. Some think this is a great move for the next generation, and some consider it a waste of…
ThinkstockViroPharma Inc. (NASDAQ: VPHM) has become the latest and greatest biotech buyout candidate after a report of it being a buyout candidate surfaced last week. We saw some 11 million shares trade hands on…
ThinkstockInvestors make big money in biotechnology stocks when they focus on areas that cut across a wide swath of the population. From obesity to food allergies to prostate cancer, the top companies often try…